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Abstract	
Bioorthogonal	 chemistry	 largely	 relies	 on	 the	 use	 of	 abiotic	 metals	 to	 catalyze	 new-to-
nature	 reactions	 in	 living	 systems.	 Over	 the	 past	 decade,	 metal	 complexes	 and	 metal-	
encapsulated	systems	such	as	nanoparticles	have	been	developed	to	unravel	the	reactivity	
of	 transition	 metals,	 including	 ruthenium,	 palladium,	 iridium,	 copper,	 iron,	 and	 gold	 in	
biological	systems.	Thanks	to	these	remarkable	achievements,	abiotic	catalysts	are	able	to	
fluorescently	 label	 cells,	 uncage	 or	 form	 cytotoxic	 drugs	 and	 activate	 enzymes	 in	
cellulo/vivo.	Recently,	strategies	for	the	delivery	of	such	catalysts	to	specific	cell	types,	cell	
compartments	or	proteins	were	established.	These	studies	reveal	the	enormous	potential	of	
this	emerging	field	and	its	application	in	both	medicinal	chemistry	and	in	synthetic	biology.		
	
Introduction	
Over	 the	 past	 decade,	 abiotic	 transition	metal-catalyzed	 reactions	 have	 successfully	 been	
introduced	 into	 living	 cells	 and	 organisms.	 With	 in	 vivo	 applications	 in	 mind,	 several	
challenges	 were	 identified	 and	 addressed:	 i)	 overcome	 the	 inherent	 cytotoxicity	 of	 the	
abiotic	 catalyst,	 ii)	 ensure	 the	 efficient	 metal	 uptake	 by	 the	 cell	 and	 iii)	 circumvent	 the	
deactivation	of	 the	 catalyst	 by	 thiols,	 proteins	 and	other	 cell	 components	 [1].	 To	 address	
these	 issues,	 several	 strategies	 were	 developed:	 i)	 metals	 were	 incorporated	 into	
nanoparticles	 or	 embedded	 in	 microspheres	 and	 resins	 (see	 sections:	 “Palladium	
nanoparticles”	 and	 “Copper	 and	 gold	 nanoparticles”;	 the	 catalyzed	 reactions	 are	
summarized	 in	 Table	 1)	 or	 ii)	 used	 as	 homogeneous	 metal	 complexes	 (see	 sections:	
“Homogenous	ruthenium	catalysts”,	“Homogenous	palladium	catalysts”	and	“Homogenous	
iron,	 iridium	 and	 gold	 catalysts”;	 the	 catalyzed	 reactions	 and	 complexes	 are	 collected	 in	
Table	 2).	 Most	 reactions	 developed	 to	 date	 are	 based	 on	 either	 a	 cleavage,	 or	 a	 cross-
coupling	 reaction.	 As	 a	 result,	 a	 variety	 of	 in	 vivo	 functions	 were	 established	 that	 are	
schematically	 presented	 in	 Figure	 1	 including:	 i)	 fluorescent	 labeling	 of	 cells,	 cell	
compartments	and	proteins,	ii)	synthesis	of	cytotoxic	agents	and	iii)	enzyme	rescue.	Several	
excellent	reviews	cover	bioorthogonal	reactions	[2-7]	or	bioorthogonal	protein	labeling	and	
protein	 chemistry	 [8-12].	 This	 review	 focuses	 on	 bioorthogonal	 transition	metal-catalyzed	
reactions	in	cellulo	(inside	single	cells	in	a	cell	culture)	and	in	vivo	(inside	living	organisms),	
highlighting	recent	developments	towards	therapeutic	applications.		
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Figure	 1.	 Strategies	 for	 the	 introduction	 of	 metal-catalyzed	 bioorthogonal	 reactions	 in	 cellulo/vivo.	
Biocompatible	 transition	 metal	 catalysts	 including	 metal-nanoparticles	 (NPs),	 NPs	 entrapped	 in	
microspheres	or	resins,	and	metal	complexes	are	taken-up	by	cells	or	 introduced	into	organisms.	These	
metal-platforms	 convert	 in	 cellulo/vivo	 various	 substrates	 through	 coupling	 or	 uncaging	 reactions	 into	
fluorophores,	 drugs	 and	 active	 enzymes.	 Recent	 progress	 allows	 to	 direct	metal	 complexes	 to	 specific	
cell-types	or	cell	compartments	such	as	organelles.		
	
Palladium	nanoparticles.	
The	use	of	metal	nanoparticles	 (NPs)	 for	 in	cellulo	catalysis	was	 first	demonstrated	by	the	
Bradley	group	[13].	They	exploited	the	biocompatibility	of	polystyrene	microspheres	[14]	by	
entrapping	 Pd-NPs,	 creating	 fluorescently-labelled	 Pd0-microspheres	 [13,15].	 These	 Pd0-
catalysts	 cleave	 allyloxycarbonyl	 (alloc)-groups,	 leading	 to	 the	 uncaging	 of	 fluorescent	
rhodamine	110	(R110)	within	the	cytoplasm	of	HeLa	cells	(Table	1,	entry	1)	[13].	Moreover,	
these	Pd0-loaded	microspheres	also	catalyze	the	Suzuki-Miyaura	cross-coupling	inside	HeLa	
cells,	leading	to	the	accumulation	of	a	rhodamine-fluorophore	within	mitochondria	(Table	1,	
entry	9)	[13].	
These	findings	suggest	that	such	Pd-NPs	may	find	applications,	both,	 in	 labeling	studies	as	
well	as	 in	medical	applications	whereby	one	can	specifically	 target	an	organelle.	With	 this	
goal	in	mind,	Broceta	and	Bradley	et	al.	 implemented	a	Pd-NP	catalyzed	drug	release.	Pd0-
NPs	were	 linked	to	polyethylene	glycol	 (PEG)-polystyrene	resins	 forming	micrometer-sized	
beads	(~150	µm)	with	a	remarkable	biocompatibility	[16].	A	single	resin	bead	was	implanted	
into	the	yolk	sac	of	zebrafish	embryos.	The	embryos	developed	normally	without	any	signs	
of	 toxicity.	 To	 prove	 the	 in	 vivo	 activity	 of	 the	 Pd0-resin,	 the	 uncaging	 of	 a	
propargyloxycarbonyl	(poc)-protected	R110	was	assayed	within	the	yolk	sac	(Table	1,	entry	
3).	 This	 Pd0	 resin	 was	 also	 able	 to	 extracellularly	 uncage	 5-fluoro-1-propargyl	 (pro)-uracil	
(pro-5FU).	This	 lead	to	the	release	of	the	cytotoxic	drug	5-flurouracil	(5FU)	in	a	cancer	cell	
culture	of	either	HCT116	or	BxPC-3	cells	(Table	1,	entry	6)	[16].	
This	 therapeutic	 strategy	 was	 refined	 by	 combining	 a	 dual	 drug	 synthesis	 strategy	 with	
tumor	 specificity	 [17].	 To	 achieve	 cell	 specificity,	 fluorescent	 Pd-microspheres	 were	
decorated	with	the	cancer	targeting	motif	cyclic-RGD	(cRGD).	cRGD	is	an	antagonist	of	the	
ανβ3	receptor,	an	angiogenesis	factor	overexpressed	in	many	tumors	and	tumor	vasculature.	
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These	 tumor-targeting	microspheres	were	 used	 for	 the	 activation	 of	 two	 prodrugs	 inside	
U87-MG	 glioblastoma	 cells.	 Besides	 uncaging	 pro-5FU,	 the	 cytotoxic	 agent	 PP-121	 was	
produced	 via	 a	 Suzuki-Miyaura	 cross	 coupling	 reaction	 leading	 to	 increased	 cell	 death,	
compared	to	the	synthesis	of	either	5FU	or	PP-121	alone	(Table	1,	entry	6	and	10)	[17].	This	
approach	 illustrates	 the	 potential	 of	 metal-NPs	 for	 targeted	 drug	 delivery	 by	 converting	
innocuous	substrates	into	active	drugs	inside	tumor	cells.	
Subsequently,	Miller	et	al.		explored	a	Pd-NP	based	drug	synthesis	strategy	in	mice	[18].	For	
this	 purpose,	 the	 palladium	 complex	 bis[tri(2-furyl)phosphine]palladium(II)-dichloride	
(PdCl2(TFP)2)	 was	 encapsulated	 into	 poly(lactic-co-glycolic	 acid)-polyethyleneglycol	 (PLGA-
PEG)-NPs,	 a	 material	 which	 is	 in	 clinical	 trials	 for	 drug	 administration	 [19].	 The	 authors	
thoroughly	studied	the	effect	of	the	nano-encapsulation,	observing	an	improved	solubility,	
bioavailability,	biocompatibility	and	a	low	cytotoxicity	(IC50	of	70-130	µM).	Furthermore,	Pd-
NPs	were	enriched	in	tumor	tissue	of	cancer	mouse	models	compared	to	other	organs	such	
as	brain,	 skin,	 lung,	bone	marrow	and	heart.	 Interestingly,	 the	highest	 catalytic	activity	of	
Pd-NPs	for	the	release	of	either	fluorescent	R110	or	the	chemotherapeutic	drug	doxorubicin	
was	 observed	 in	 tumor	 tissue	 (Table	 1,	 entry	 1	 and	 2).	 Therefore,	 combining	 nano-
encapsulated	 Pd-NPs	 and	 caged	 doxorubicin	 helped	 to	 minimize	 systemic	 exposure	 and	
toxicity,	 thus	 increasing	 the	 maximum-tolerated	 dose	 by	 300	 %,	 resulting	 in	 the	 halt	 of	
tumor	growth	and	extending	the	survival	of	tumor-bearing	mice	[18].		
	
Copper	and	gold	nanoparticles.	
The	range	of	metal-NPs	was	recently	broadened	to	include	Cu	[20,21]	and	Au	[22,23],	thus	
expanding	the	in	vivo	catalytic	repertoire.	Although	CuI-catalyzed	azide-alkyne	cycloaddition	
(CuAAC)	has	been	known	since	2002	 [24,25],	 it	was	hardly	used	 in	vivo	due	 to	 its	marked	
cytotoxicity	 [26].	 The	 incorporation	 of	 Cu	 into	 aspartate-containing	 polyolefins	 [20]	 or	
entrapping	 Cu	 in	 TentaGel	 resin	 [21],	 contributed	 to	 overcoming	 these	 biocompatibility	
issues.	 On	 the	 one	 hand,	 Cu-based	 NPs	 convert	 coumarin-derivatives	 via	 CuAAC	 into	
fluorophores	inside	NCI-H460	and	MDA-MB-231	cancer	cells	(Table	1,	entry	12)	[20].	On	the	
other	hand,	Cu-particles	produce	 in	cellulo	cytotoxic	agents,	decreasing	the	cell	viability	of	
Escherichia	coli	(Table	1,	entry	14)		[20].	Furthermore,	the	implantation	of	the	Cu-resin	into	
the	yolk	sac	of	zebrafish	embryos	did	not	exhibit	any	toxicity	but	catalyzed	the	release	of	a	
coumarin-fluorophore	(Table	1,	entry	13)		[21].		
Besides	Cu	and	Pd,	 gold	was	 immobilized	on	a	 solid	 support,	 a	polyethylene	glycol	 (PEG)-
grafted	 low-cross-linked	polystyrene	matrix	 [22].	This	Au-resin	was	employed	 for	 the	 local	
release	of	R110	 in	 the	brain	of	 zebrafish	 (Table	1,	entry	3)	as	well	as	 for	 the	activation	of	
structurally	 diverse	 prodrugs	 inside	 A549	 cancer	 cells	 (Table	 1,	 entry	 5,	 7	 and	 8).	 This	
demonstrates	 the	 potential	 application	 of	 Au-resin	 for	 in	 vivo	 drug-release	 [22].	
Furthermore,	 Tonga	et	 al.	 created	 controllable,	 Au-NPs	 by	 blocking	 the	 access	 to	 the	Au-
encapsulated,	catalytic	Ru-	or	Pd-complexes	[23].	This	‘gate-keeping’	was	achieved	through	
steric	 hindrance	 by	 supramolecular	 binding	 of	 cucurbit[7]uril	 onto	 the	 surface.	 The	 NPs	
were	activated	 through	 the	addition	of	 a	 competitor,	 1-adamantylamine	 to	unmask	alloc-
R110	 (by	Ru-	and	Pd-loaded	NPs)	and	 the	prodrug	pro-5FU	 (by	Pd-loaded	NPs)	 inside	 live	
HeLa	cells	(Table	1,	entry	1	and	6)	[23].	These	gated	NPs	reduce	the	interference	with	cell	
components,	 protect	 the	 metal	 from	 poisoning	 and	 increase	 the	 biocompatibility.	
Moreover,	 the	 introduction	 of	 a	 switch	 into	 these	 NPs	 allows	 a	 more	 controlled	 drug	
treatment	and	suggests	their	use	for	restoring	malfunctioning	pathways	in	chronic	disease.	
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Table	1:	Reactions	catalyzed	by	metal	loaded	nanoparticles	
Entry	 Reaction	 Catalyst	 Organism	 Ref.	
	 Allyloxycarbonyl	cleavage	 	 	 	
1	
O NHHN O NH2H2N
Rhodamine 110
O O OO
O
O
COO
	
Entrapped	
Pd-NPs	
Free	Pd-NPs	
	
	
	
	
Ru/Pd-
complex	
entrapped	in	
Au-NPs	
HeLa	cells	
	
HT1080,	
ID8,	
A2780CP	
cells;	mouse	
model;	
HeLa	cells		
[13,15]	
	
[18]	
	
	
	
	
[23]	
	
	
2	
OMe O
O OH
OH O H
O
O
OH
OH
OH
H
N O
O
OMe O
O OH
OH O H
O
O
OH
OH
OH
NH2
Doxorubicin 	
Free	Pd-NPs	
	
Mouse	
model	
[18]	
	
	 Propargyloxycarbonyl	cleavage	 	 	 	
3	
O NHHN O NH2H2N
Rhodamine 110
O O OO
O
O
COO
	
Entrapped	
Pd-NPs		
Entrapped	
Au-NPs	
Zebrafish	
	
Zebrafish		
[16]	
	
[22]	
4	
N
O NHN
N
O NHH2N
O O OO
Cresyl violet 	
Entrapped	
Pd-NPs		
	
U87-MG	
cells	
[17]	
5	
OMe O
O OH
OH O H
O
O
OH
OH
OH
H
N O
O
OMe O
O OH
OH O H
O
O
OH
OH
OH
NH2
Doxorubicin 	
Entrapped	
Au-NPs	
A549	cells	 [22]	
	 Propargyl	cleavage	 	 	 	
6	
N
NH
O
O
F
N
H
NH
O
O
F
5FU 	
Entrapped	
Pd-NPs		
	
	
	
Pd-complex	
entrapped	in	
Au-NPs	
HCT116,	
BxPC-3	cells;	
U87-MG	
cells;	
HeLa	cells	
[16]	
	
[17]	
	
	
[23]	
7	
N
N
O
O
F
O
OH
HO N
NH
O
O
F
O
OH
HO
FUdR 	
Entrapped	
Au-NPs	
A549	cells	 [22]	
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Table	1	(continued)	
Entry	 Reaction	 Catalyst	 Organsim	 Ref.	
	 Propargyloxyaryl	cleavage	 	 	 	
8	
O
ON
H
O
HN
O
OHN
H
O
HN
O Vorinostat 	
Entrapped	
Au-NPs	
A549	
cells	
[22]	
	 Suzuki-Miyaura	cross-coupling	 	 	 	
9	
O OO
OOO
O
COO
S
CF3
OO
+
O
B O
NH
P
N
Ph3P
	
Entrapped	
Pd-NPs	
HeLa	
cells	
[13,15]	
10	
N
N N
N
NH2 I
+
O
B O
N
NH
N
H
N
N
N N
N
NH2
PP-127 	
Entrapped	
Pd-NPs	
U87-MG	
cells	
[17]	
	 Heck	Coupling	 	 	 	
11	
O O
I
N O ON
	
Free	Pd-
NPs	
HT80	
cells	
[18]	
	 Azide–alkyne	cycloaddition	 	 	 	
12	
OHO O
N3
+
OMe
OHO O
N N
N
OMe 	
Free	Cu-
NPs	
	
	
	
NCI-
H460,	
MDA-
MB-231	
cells;	
	
[20]	
	
	
	
13	
OHO O
N3
+
H
N
O
PPh3
OHO O
N N
N
NH
O
PPh3
	
Entrapped	
Cu-NPs	
Zebrafish	 [21]	
14	
N
NH
N
H
O
N
NH
N
H
O
N3
+
N
NH
N
H
O
N N
N
N
H
O
N
NH
Bisamidine 	
Free	Cu-
NPs	
	
E.	coli	 [20]	
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Homogenous	ruthenium	catalysts	
Streu’s	and	Meggers’	seminal	work	on	 in	cellulo	catalyzed	Ru-reactions	laid	the	foundation	
of	bioorthogonal	organometallic	chemistry	 [27].	 In	2006,	 they	suggested	that	 the	complex	
[Cp*Ru(cod)Cl]	 Ru1	 (Cp*=pentamethylcyclopentadienyl,	 cod=1,5-cyclooctadiene,	 Table	 2,	
entry	1)	catalyzes	the	uncaging	of	alloc-protected	R110	inside	HeLa	cells,	while	not	affecting	
the	 cell	 viability	 [27].	 In	 2014	 and	 2017,	 they	 reported	 on	 significantly	 more	 active	 Ru-
pianostool	complexes	Ru2-Ru6	(Table	2,	entry	1	and	4)	catalyzing	alloc-unmasking		[28,29].	
Moreover,	alloc-protecting	groups	were	cleaved	off	from	DNA-binding	agents	such	as	4’,6-
diamidino-2-phenylindole	 (DAPI)	 and	 ethidium	 bromide	 inside	 chicken	 embryo	 fibroblasts	
(CEF)	and	the	kidney	epithelial	cell	line	Vero	(Table	2,	entry	2	and	3)		[30].		
Subsequently,	 the	 quinolone	 based	 Ru-complex	 was	 improved	 by	 reducing	 the	 π-
backbonding	of	 the	bidentate	 ligand	 (Ru2-Ru4)	and	 improving	 the	 in	vivo	R110	release	by	
130-fold,	 comparing	 Ru4	 to	 Ru1	 [28].	 Furthermore,	 Ru4	 unmasked	 efficiently	 alloc-
doxorubicin,	triggering	the	apoptosis	of	HeLa	cells	[28].	Very	recently,	the	activity	of	the	Ru-
complex	 was	 further	 enhanced	 tenfold	 by	 replacing	 the	 quinoline	 of	 Ru4	 with	 an	 8-
hydoxiquinolate	 motif	 (Ru5	 and	 Ru6)	 [29].	 Ru6	 decages	 almost	 quantitatively	 alloc-
doxorubicin	decreasing	the	IC50	concentration	of	alloc-doxorubicin	from	15	µM	to	2	µM	in	
the	presence	of	1	µM	Ru4	or	Ru6,	respectively	[29].	ICP-MS	studies	reported	by	Wender	et	
al.	however	suggest	that	the	Ru-complex	Ru3	does	not	penetrate	into	the	cytoplasm	of	4T1	
cells,	indicating	that	the	reaction	occurs	extracellularly	[31].	To	overcome	this	shortcoming,	
Mascareñas	et	al.	appended	a	cation	triphenylphosphonium	(TPP)	moiety	to	Ru2	to	afford	
Ru7	 (Table	 2,	 entry	 1)	 [32].	 Such	 lipophilic	 cations	 are	 taken	 up	 by	mitochondria	 [33,34].	
After	 treading	 HeLa	 cells	 with	 Ru7	 and	 caged-R110,	 fluorescence	 was	 measured	 within	
mitochondria.	 This	 suggests	 that	 Ru7	 is	 present	 in	 the	 mitochondria,	 thanks	 to	 the	 TPP	
targeting	moiety	[32].	To	improve	the	traceability	of	Ru7,	a	pyrene	derivative	was	added	to	
afford	 Ru8	 (Table	 2,	 entry	 1),	 enabling	 fluorescent	 monitoring	 of	 the	 complex	 itself.	 As	
anticipated,	 both	 the	 catalyst	Ru8	 and	 R110	were	 localized	 inside	 the	mitochondria.	 The	
authors	 specifically	 depolarized	 mitochondria	 by	 deprotecting	 the	 proton	 ionophore	 2,4-
dinitrophenol	 (Table	 2,	 entry	 5)	 [35,36],	 demonstrating	 the	 potential	 of	 organelle-specific	
complexes	for	disturbing	and	modifying	biological	systems	[32].	
A	 different	 approach	 to	 target	 cell	 compartments	 and	 proteins	 was	 pursued	 by	 the	
Winssinger	 lab	 [37-39].	 A	 Ru-complex	 (Ru10,	 Table	 2,	 entry	 6)	 was	 linked	 to	 a	 peptide	
nucleic	acid	 (PNA)-probe	which	hybridizes	with	tissue	specific	miRNAs	[39].	The	Ru10-PNA	
and	 a	 fluorogenic	 rhodamine-PNA	 were	 injected	 into	 a	 one-cell	 zebrafish	 embryo.	 Using	
PNA-recognition	 sequences	 on	 both	 the	 catalyst	 and	 the	 azide-bearing	 substrate	 ensures	
the	photocatalytic	reduction	of	the	azide	upon	docking	of	the	substrate	and	catalyst	to	the	
target	miRNA.	This	yields	fluorescence	in	the	specific	tissues	of	live	zebrafish.	The	same	Ru-
complex	conjugated	to	an	epidermal	growth	factor	receptor	(EGFR)-inhibitor,	Ru11,	and	an	
estrogen	 agonist	 (raloxifene),	Ru12,	 (Table	 2,	 entry	 7)	 targeted	 the	 receptor	 proteins	 and	
provided	a	spatial	and	temporal	unmasking	of	the	fluorescent	dye	in	live	HEK293T	and	MCF-
7	cells	[38].		
By	targeting	a	biotinylated	Ru-cofactor	Ru13	to	streptavidin	(Sav)	in	E.	coli,	The	Ward	group	
could	evolve	an	artificial	metalloenzyme	 in	cellulo	 (Table	2,	entry	8)	[40].	Fusing	the	signal	
peptide	of	the	outer	membrane	protein	A	(OmpA)	to	Sav	lead	to	the	efficient	secretion	of	
the	overexpressed	Sav	into	the	periplasm	of	E.	coli.	Addition	of	Ru13	to	these	cells	allowed	
the	 assembly	 of	 an	 artificial	metalloenzyme	Ru13·Sav	within	 the	 periplasm	of	E.	 coli.	 The	
resulting	strain	catalyzed	the	ring	closing	metathesis	(RCM)	of	an	umbelliferone	precursor	in	
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the	periplasm	of	E.	 coli.	 The	catalytic	performance	of	Ru13·Sav	was	 improved	by	directed	
evolution	relying	on	the	fluorescence	of	the	formed	umbelliferone.	The	evolved	strain	was	
shown	 to	 catalyze	 the	 RCM	 of	 typical	 diolefin	 substrates,	 leading	 to	 660	 TONs,	
outperforming	the	standard	homogeneous	RCM	catalysts		[40].	
	
Homogeneous	palladium	catalysts	
To	the	best	of	our	knowledge,	 the	 first	homogeneous	Pd-catalyzed	reaction	 in	cellulo	was	
reported	by	Lin	et	al.	 [41].	A	copper-free	Sonogashira	cross-coupling	reaction	was	used	to	
selectively	 label	 homopropargylglycine	E.	 coli	cells.	 Fluorescein	 iodide	was	 coupled	 to	 the	
metabolically	 incorporated	 homopropargyglycine,	 by	 a	 newly	 discovered	 Pd-complex	Pd1	
(Table	2,	entry	9)	[41].	
Subsequently,	unnatural	amino	acids	(UAAs)	were	genetically	encoded	by	amber	stop	codon	
suppression	[42,43]	and	p-iodophenylalanine	was	incorporated	on	the	external	loops	of	the	
bacterial	pore	protein	OmpC	[44].	The	palladium	complex	Pd1	coupled	a	fluorescent	boronic	
acid	to	the	p-iodophenylalanine	of	the	OmpC-mutants	via	Suzuki-Miyaura	cross-coupling	on	
the	 surface	 of	 live	 E.	 colis	 (Table	 2,	 entry	 12)	 [44].	 Furthermore,	 proteins	 carrying	 an	
encoded	alkyne	were	cross-coupled	via	a	Sonogashira	reaction	with	a	fluorophore	bearing	a	
iodophenyl	group	(Iph-FL-525)	using	[Pd(NO3)2]	inside	E.	coli	and	Shigella	(Table	2,	entry	10)		
[45].		
The	Pd-catalyzed	fluorescent	labeling	of	UAAs	was	also	expanded	to	mammalian	cells	[46].	
Nε-butynyloxycarbonyllysine	 encoded	 in	 the	 EGFR-protein	 was	 cross-coupled	 to	 biotin-
phenyl	 iodide	using	catalyst	Pd1	(Table	2,	entry	11).	The	biotinylated	EGFR	was	monitored	
by	fluorescence	through	addition	of	Sav	conjugated	to	Alexa	Fluor®	568	[46].	
Besides	labeling	specific	proteins	 in	vivo,	Chen	and	coworkers	were	the	first	to	employ	Pd-
complexes	 for	 a	 gain-of-function	 study,	 using	 a	 deprotection-strategy	 [47].	 The	
phosphothreonine	 lyase	 OspF	 was	 blocked	 by	 masking	 the	 catalytic	 Lys134	 with	 a	 poc-
group.	 The	 catalyst	 [Pd(η3-allyl)Cl]2	 Pd3	 (Table	 2,	 entry	 14)	 cleaved	 the	 poc-OspF	 and	
allowed	the	in	vivo	monitoring	its	substrate,	the	Erk	kinase,	in	HeLa	cells	[47].	This	gain-of-
function	 approach	 was	 extended	 by	 incorporating	 the	 UAA	 allenyl-tyrosine	 that	 can	 be	
uncaged	 thanks	 to	 homogeneous	 Pd-catalysts	 Pd3-Pd6	 (Table	 2,	 entry	 15)	 [48].	 The	
following	enzymes	were	rescued	by	allenyl-removal	through	Pd3-Pd6	in	HEK293T	cells:	Taq	
DNA	polymerase,	Src	kinase	and	the	anthrax	lethal	factor	endopeptidase	[48].	
Recently,	 cell-penetrating	 peptides	 were	 linked	 to	 a	 Pd-complex	 Pd7	 (Table	 2,	 entry	 13),	
improving	its	 internalization	(Table	2,	entry	13)	[49].	The	uncaging	of	poc-R110	in	prostate	
adenocarcinoma	(PC-3)	cells	was	demonstrated	[49].	The	peptide-based	platform	facilitates	
the	 delivery	 of	 metal-complexes	 to	 specific	 cell-types,	 thus	 opening	 the	 possibility	 of	
targeted	drug	delivery	[50,51].		
	
Homogenous	iron,	iridium	and	gold	catalysts	
Besides	Ru-	and	Pd-complexes,	other	metals	have	been	employed	for	intracellular	labeling:	
An	 iron(III)	 meso-tetraarylporphin	 Fe1	 (Table	 2,	 entry	 16)	 was	 shown	 to	 catalyze	 azide	
reduction	leading	to	the	release	of	R110	in	HeLa	cells	[52].	The	Ir-complex	Ir1	(Table	2,	entry	
17)	reduces	an	aldehyde	 leading	to	the	release	of	a	 fluorescent	Bodipy-OH	 inside	NIH-3T3	
cells	[53].	A	more	sophisticated	Au-catalyzed	approach	was	developed	by	Tanaka	et	al.	[54].	
They	relied	on	an	Au-complex	linked	to	coumarin,	Au1	(Table	2,	entry	18	and	19)	which	has	
marked	affinity	for	albumin.	These	albumins	were	coated	with	glycans	through	the	“RIKEN	
click”	reaction,	influencing	the	trafficking	pathways	and	resulting	in	an	accumulation	either	
8	
on	 the	 liver	 or	 the	 intestine	 by	 using	 (2-6)-disialoglycoalbumin	 or	 galactosylglycoalbumin,	
respectively.	 These	 organ-targeted	 Au-complexes	 catalyzed	 an	 amide	 bond	 formation	
between	a	propargyl-ester	of	fluorescent	probes	(TAMRA-O-pro,	Cy7.5-O-pro)	and	surface-	
exposed	amines	of	nearby	proteins	 leading	 to	an	organ-specific	 labeling	 inside	 living	mice	
[54].		
	
Conclusions	
Since	 2014,	 the	 field	 of	 metal-catalyzed	 bioorthogonal	 reactions	 has	 made	 significant	
progress.	Initially,	it	was	demonstrated	that	metal-NPs	and	metal	complexes	can	uncage	or	
synthesize	 drugs	 in	 cellulo/vivo.	 Subsequently,	 the	 specificity	 of	 these	 metal-based	
platforms	was	considerably	improved.	Now,	it	is	possible	to	target	specific	organs,	cells,	cell	
compartments	and	certain	proteins.	Thanks	to	these	efforts,	one	can	envision	the	possibility	
of	targeting	and	killing	cells	as	well	as	gaining	abiotic	cellular	functions.		
The	 exploitation	 of	 novel	 targeting	 and	 packaging	 strategies	 should	 further	 contribute	 to	
decreasing	 the	 toxicity	of	 the	metal	 catalysts	and	 increasing	 their	 specificity.	 This	extends	
the	safety	window	of	metal	catalysts	in	vivo,	hopefully	resulting	in	the	development	of	new	
therapies.	Beyond	clinical	applications,	one	can	envisage	to	design	bioorthogonal	metabolic	
pathways	in	cellulo/vivo	for	the	production	of	high-value	chemicals.		
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Table	2:	Reactions	catalyzed	by	metal-	complexes	in	a	biological	environment	
Entry	 Reaction	 Catalyst	 Organism	 Ref.	
	 Allyloxycarbonyl	cleavage	 Ruthenium	 	 	
1	
O NHHN O NH2H2N
Rhodamine 110
O O OO
O
O
COO
	
Ru Cl
Ru1
	
N
O
Ru
PF6—
Ru2 -H
Ru3 -OMe
Ru4 -NMe2O
R
	
	
N
O
Ru
PF6—
O
R
PPh
Ph
Ph
O N
O
Ru7
P O N
O
Ru8
Ph
Ph
N
H
N Ru9
O
=R
=R
=R
	
 
HeLa	cells	
	
	
	
HeLa	cells	
	
	
	
	
	
HeLa	cells	
and	
mitochondria	
of	HeLa	cells	
	
[27]	
	
	
	
[28]	
	
	
	
	
	
[32]	
	
	
	
	
	
2	
N
H
H
N
NH
O
O
H
N
HN
O
O N
H
NH2
NH
H2N
HN
DAPI 	
Ru Cl
Ru1
	
CEF,	Vero	
cells		
[30]	
3	
N
HN
O
O
NH
O
O N
H2N NH2
Ethidium bromide 	
Ru Cl
Ru1
	
CEF	cells	 [30]	
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Table	2	(continued)	
Entry	 Reaction	 Catalyst	 Organism	 Ref.	
	 Allyloxycarbonyl	cleavage	 Ruthenium	 	 	
4	
OMe O
O OH
OH O H
O
O
OH
OH
OH
H
N O
O
OMe O
O OH
OH O H
O
O
OH
OH
OH
NH2
Doxorubicin 	
N
O
Ru
PF6—
Ru2 -H
Ru3 -OMe
Ru4 -NMe2O
R
	
N
O
Ru
PF6—
R Ru5 -HRu6 -CO2Me  
HeLa	cells	
	
	
	
	
HeLa	cells		
	
[28]	
	
	
	
	
[29]	
	 Allyl	cleavage	 Ruthenium	 	 	
5	
2,4-dinitrophenol
O
NO2
O2N
O
NO2
O2N
	
N
O
Ru
PF6—
O
R
P O N
O
Ru8
Ph
Ph
N
H
N Ru9
O
=R
=R
	
HeLa	cells	and	
mitochondria	
of	HeLa	cells	
	
[32]	
	
	 Photocatalyzed	azide	reduction	 Ruthenium	 	 	
7	
N
NHCl
O
Cl
O
OON3
N
NHCl
O
Cl
HO 	
N
N
N
N
N
N
Ru
N
H
S
NH
PNA
Ru10 	
Zebrafish	 [39]	
6	
N
NHCl
O
Cl
O
OON3
N
NHCl
O
Cl
HO 	
N
N
N
N
N
N
Ru
N
H
S
N
H
Ru11
HN O
OH O
O
N
	
N
N
N
N
N
N
Ru
N
H
S
N
H
Ru12
O O
H
N O
O
O
S
OH
OH 	
HEK293T,	
MCF-7	cells	
[38]	
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Table	2	(continued)	
Entry	 Reaction	 Catalyst	 Organism	 Ref.	
	 Ring	closing	metathesis	 Ruthenium	 	 	
8	
O OHO O OHO
Umbelliferone 	
N N
Ru
O
Cl
Cl
H
N
O
Sav   Biot
Ru13
 
Periplasm	of	
E.	coli	
[40]	
	 Copper-free	Sonogashira	cross-coupling	 			Palladium	 	 	
9	
+
O
O
HO
I
COOH
Ubiquitin
O
O
HO
COOH
Ubiquitin
Fluorescein 	
N
N
NaO
NaO
N Pd(OAc)2
2
Pd1
	
E.	coli	
	
[41]	
	
10	
H
N
NH
S
O
H
N O
O
I
+
HN
EGFR-EGFP
O
O
HN NH
S
O
H
N
O
O
O N
H
O
EGFR-EGFP
Biotin
	
N
N
NaO
NaO
N Pd(OAc)2
2
Pd1
	
HEK293	 [46]	
	
11	 OHN HN
OOC
H
N O
O
O N
H
O
I
+
Protein O
H
N
H
N
OOC
H
N O
O
O N
H
O
Protein
Fluor 525
	
Pd(NO3)2	(Pd2)	
	
E.	coli	and	
Shigella	
	
	
	
[45]	
	
	
	
	
	
	 Suzuki-Miyaura	cross-coupling	 Palladium 	 	
12	 O OHO O OHO
O
O
COOH
+
B(OH)2
I
OmpC
OmpC 	
N
N
NaO
NaO
N Pd(OAc)2
2
Pd1
 
E.	coli	 [40,44]	
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Table	2	(continued)	
Entry	 Reaction	 Catalyst	 Organism	 Ref.	
	 Propargyloxycarbonyl	cleavage	 Palladium	 	 	
13	
	
O NHHN O NH2H2N
Rhodamine 110
O O OO
O
O
COO
	
[Pd(η3-allyl)Cl]2	(Pd3)	
Pd(dba)2	(Pd4)	
 
 
 
 
N
PdN
N
N
H
O
[AA]n NH2
Pd7
	
HEK293T,	NIH-
3T3,	A549,	
HeLa,	Caco-2,	
CHO	cells	
	
PC-3	cells	
[47]	
[41]	
	
	
	
[49]	
14	
OspF
H
N
O
O OspF NH2
Lysine 	
[Pd(η3-allyl)Cl]2	(Pd3)	
Pd(dba)2	(Pd4)	
HeLa	cells	 [47]	
	 Allenyl	cleavage	 Palladium	 	 	
15	 O OH
Protein Protein
Tyrosine
	
[Pd(η3-allyl)Cl]2	(Pd3)	
Pd(dba)2	(Pd4)	
Pd(TAPAd)2	(Pd5)	
Pd(TPPTS)4	(Pd6) 
HEK293T	cells		
	
	
[48]	
	 Bisazide	reduction	 Iron 	 	
16	 O N3N3 O NH2H2N
Rhodamine 110
O
O
COO
	
N N
NN
Fe
Cl
Ph
Ph
Ph Ph
Fe1
 
HeLa	cells	 [40,52]	
	 Transfer	Hydrogenation	 Irridium 	 	
17	
N
N
H
O
BF
F N
N OH
BF
F
Bodipy-OH 	
Ir1
Ir ClN
N
O  
NIH-3T3	cells	 [41,53]	
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Table	2	(continued)	
Entry	 Reaction	 Catalyst	 Organism	 Ref.	
	 Amide	bond	formation	 Gold	 	 	
18	
N N
O
H
N
O
N
H O
H
N
NH
HN NH2
O
O
ProteinH2N
N N
O
H
N
O
N
H O
H
N
NH
HN NH2
O
N
H
Protein
Cy7.5
	
N Au
Cl Cl
NON
H
ON
H
O
3
O
O
Et2N
O
Au1
 
Mouse	liver	
and	intestine	
[54]	
19	 O NMe2Me2N
COO
H
N
O
N
H
O
O
O
H2N Protein
O NMe2Me2N
COO
H
N
O
N
H
H
N
O
O
Protein
TAMRA
	
N Au
Cl Cl
NON
H
ON
H
O
3
O
O
Et2N
O
Au1
 
Mouse	liver	
and	intestine	
[54]	
14	
	
Acknowledgments:	TRW	thanks	the	ERC	(The	DrEAM)	and	the	NCCR	Molecular	Systems	
engineering	for	generous	support	of	his	work	in	this	field.	JGR	thanks	EMBO	for	a	Long-Term	
fellowship	(EMBO	ALTF	194-2017).	
	
References	and	recommended	reading	
Papers	of	particular	interest,	published	within	the	period	of	review,	have	been	highlighted	
as:	
•	of	special	interest	
••	of	outstanding	interest	
	
1.	Wilson	YM,	Durrenberger	M,	Nogueira	ES,	Ward	TR:	Neutralizing	the	detrimental	effect	
of	glutathione	on	precious	metal	catalysts.	J	Am	Chem	Soc	2014,	136:8928-8932.	
2.	Sletten	EM,	Bertozzi	CR:	Bioorthogonal	chemistry:	fishing	for	selectivity	in	a	sea	of	
functionality.	Angew	Chem	Int	Ed	Engl	2009,	48:6974-6998.	
3.	Sasmal	PK,	Streu	CN,	Meggers	E:	Metal	complex	catalysis	in	living	biological	systems.	
Chem	Commun	(Camb)	2013,	49:1581-1587.	
4.	Patterson	DM,	Nazarova	LA,	Prescher	JA:	Finding	the	right	(bioorthogonal)	chemistry.	
ACS	Chem	Biol	2014,	9:592-605.	
5.	Chankeshwara	SV,	Indrigo	E,	Bradley	M:	Palladium-mediated	chemistry	in	living	cells.	
Curr	Opin	Chem	Biol	2014,	21:128-135.	
6.	Volker	T,	Meggers	E:	Transition-metal-mediated	uncaging	in	living	human	cells-an	
emerging	alternative	to	photolabile	protecting	groups.	Curr	Opin	Chem	Biol	2015,	
25:48-54.	
7.	Li	J,	Chen	PR:	Development	and	application	of	bond	cleavage	reactions	in	bioorthogonal	
chemistry.	Nat	Chem	Biol	2016,	12:129-137.	
8.	Spicer	CD,	Davis	BG:	Selective	chemical	protein	modification.	Nat	Commun	2014,	5:4740.	
9.	Yang	M,	Li	J,	Chen	PR:	Transition	metal-mediated	bioorthogonal	protein	chemistry	in	
living	cells.	Chem	Soc	Rev	2014,	43:6511-6526.	
10.	Gong	Y,	Pan	L:	Recent	advances	in	bioorthogonal	reactions	for	site-specific	protein	
labeling	and	engineering.	Tetrahedron	Lett	2015,	56:2123-2132.	
11.	Chen	X,	Wu	YW:	Selective	chemical	labeling	of	proteins.	Org	Biomol	Chem	2016,	
14:5417-5439.	
12.	Schwizer	F,	Okamoto	Y,	Heinisch	T,	Gu	Y,	Pellizzoni	MM,	Lebrun	V,	Reuter	R,	Kohler	V,	
Lewis	JC,	Ward	TR:	Artificial	Metalloenzymes:	Reaction	Scope	and	Optimization	
Strategies.	Chem	Rev	2017,	doi:	10.1021/acs.chemrev.7b00014.	
•		
This	 is	 a	 comprehensive	 review	 about	 artificial	 metalloenzymes	 (ArMs).	 Used	 scaffold	 proteins,	
anchoring	 strategies	 and	 metallocofactors	 are	 discussed.	 Mutagenesis	 approaches	 for	 the	 the	
evolution	of	ArMs	are	reviewed.	The	ArMs	are	organized	by	reaction	class.	
	
13.	Yusop	RM,	Unciti-Broceta	A,	Johansson	EM,	Sanchez-Martin	RM,	Bradley	M:	Palladium-
mediated	intracellular	chemistry.	Nat	Chem	2011,	3:239-243.	
14.	Alexander	LM,	Pernagallo	S,	Livigni	A,	Sanchez-Martin	RM,	Brickman	JM,	Bradley	M:	
Investigation	of	microsphere-mediated	cellular	delivery	by	chemical,	microscopic	
and	gene	expression	analysis.	Mol	Biosyst	2010,	6:399-409.	
15	
15.	Unciti-Broceta	A,	Johansson	EM,	Yusop	RM,	Sanchez-Martin	RM,	Bradley	M:	Synthesis	of	
polystyrene	microspheres	and	functionalization	with	Pd(0)	nanoparticles	to	
perform	bioorthogonal	organometallic	chemistry	in	living	cells.	Nat	Protoc	2012,	
7:1207-1218.	
16.	Weiss	JT,	Dawson	JC,	Macleod	KG,	Rybski	W,	Fraser	C,	Torres-Sanchez	C,	Patton	EE,	
Bradley	M,	Carragher	NO,	Unciti-Broceta	A:	Extracellular	palladium-catalysed	
dealkylation	of	5-fluoro-1-propargyl-uracil	as	a	bioorthogonally	activated	prodrug	
approach.	Nat	Commun	2014,	5:3277.	
17.	Clavadetscher	J,	Indrigo	E,	Chankeshwara	SV,	Lilienkampf	A,	Bradley	M:	In-Cell	Dual	
Drug	Synthesis	by	Cancer-Targeting	Palladium	Catalysts.	Angew	Chem	Int	Ed	Engl	
2017,	56:6864-6868.	
••		
Pd-microspheres	were	coated	with	cyclic-RGD	to	target	cancer	cells.	The	microspheres	catalyze	the	
formation	of	two	anticancer	agents	5FU	and	PP-121.	The	catalyzed	reactions	are	propargyl	cleavage	
and	 Suzuki-Miaura	 cross-coupling.	 The	 dual-drug	 synthesis	 strategy	was	 evaluated	 in	 brain	 cancer	
cells.	
	
18.	Miller	MA,	Askevold	B,	Mikula	H,	Kohler	RH,	Pirovich	D,	Weissleder	R:	Nano-palladium	is	
a	cellular	catalyst	for	in	vivo	chemistry.	Nat	Commun	2017,	8:15906.	
••		
Thorough	 study	 of	 a	 nanoencapsulated	 Pd-catalyst.	 The	 biocompatibility,	 localization	 in	mice	 and	
use	for	drug	release	were	investigated.	The	Pd-compound	uncages	doxorubicin	and	catalyzes	a	Heck	
coupling	in	cellulo.		
	
19.	Hrkach	J,	Von	Hoff	D,	Mukkaram	Ali	M,	Andrianova	E,	Auer	J,	Campbell	T,	De	Witt	D,	Figa	
M,	Figueiredo	M,	Horhota	A,	et	al.:	Preclinical	development	and	clinical	translation	
of	a	PSMA-targeted	docetaxel	nanoparticle	with	a	differentiated	pharmacological	
profile.	Sci	Transl	Med	2012,	4:128ra139.	
20.	Bai	Y,	Feng	X,	Xing	H,	Xu	Y,	Kim	BK,	Baig	N,	Zhou	T,	Gewirth	AA,	Lu	Y,	Oldfield	E,	et	al.:	A	
Highly	Efficient	Single-Chain	Metal-Organic	Nanoparticle	Catalyst	for	Alkyne-Azide	
"Click"	Reactions	in	Water	and	in	Cells.	J	Am	Chem	Soc	2016,	138:11077-11080.	
21.	Clavadetscher	J,	Hoffmann	S,	Lilienkampf	A,	Mackay	L,	Yusop	RM,	Rider	SA,	Mullins	JJ,	
Bradley	M:	Copper	Catalysis	in	Living	Systems	and	In	Situ	Drug	Synthesis.	Angew	
Chem	Int	Ed	Engl	2016,	55:15662-15666.	
22.	Perez-Lopez	AM,	Rubio-Ruiz	B,	Sebastian	V,	Hamilton	L,	Adam	C,	Bray	TL,	Irusta	S,	
Brennan	PM,	Lloyd-Jones	GC,	Sieger	D,	et	al.:	Gold-Triggered	Uncaging	Chemistry	in	
Living	Systems.	Angew	Chem	Int	Ed	Engl	2017.	
•		
The	Au-resin	catalyzes	the	uncaging	of	several	prodrugs	 in	A549	cancer	cell	cultures.	Next,	 the	Au-
resin	 was	 implanted	 into	 a	 zebrafish	 brain.	 The	 fluorophore	 rhodamine	 110	 was	 efficiently	
deprotected	inside	the	brain.	
	
23.	Tonga	GY,	Jeong	Y,	Duncan	B,	Mizuhara	T,	Mout	R,	Das	R,	Kim	ST,	Yeh	YC,	Yan	B,	Hou	S,	
et	al.:	Supramolecular	regulation	of	bioorthogonal	catalysis	in	cells	using	
nanoparticle-embedded	transition	metal	catalysts.	Nat	Chem	2015,	7:597-603.	
••	
Pd-	 and	 Ru-complexes	were	 encapsulated	 in	 Au-nanoparticles.	 The	 activity	 of	 these	 catalysts	was	
controlled	by	a	supramolecular	'gate-keeper'.	Unmasking	reactions	were	catalyzed	after	the	addition	
16	
of	the	competitive	activator.	Rhodamine	110	and	the	cytotoxic	drug	5FU	were	released	in	live	HeLa	
cells.	The	reversible	switch	allowed	a	temporal	controlled	release	of	product.		
	
24.	Tornoe	CW,	Christensen	C,	Meldal	M:	Peptidotriazoles	on	solid	phase:	[1,2,3]-triazoles	
by	regiospecific	copper(i)-catalyzed	1,3-dipolar	cycloadditions	of	terminal	alkynes	
to	azides.	J	Org	Chem	2002,	67:3057-3064.	
25.	Rostovtsev	VV,	Green	LG,	Fokin	VV,	Sharpless	KB:	A	stepwise	huisgen	cycloaddition	
process:	copper(I)-catalyzed	regioselective	"ligation"	of	azides	and	terminal	
alkynes.	Angew	Chem	Int	Ed	Engl	2002,	41:2596-2599.	
26.	Liang	L,	Astruc	D:	The	copper(I)-catalyzed	alkyne-azide	cycloaddition	(CuAAC)	“click”	
reaction	and	its	applications.	An	overview.	Coord	Chem	Rev	2011,	255:2933-2945.	
27.	Streu	C,	Meggers	E:	Ruthenium-induced	allylcarbamate	cleavage	in	living	cells.	Angew	
Chem	Int	Ed	Engl	2006,	45:5645-5648.	
28.	Volker	T,	Dempwolff	F,	Graumann	PL,	Meggers	E:	Progress	towards	bioorthogonal	
catalysis	with	organometallic	compounds.	Angew	Chem	Int	Ed	Engl	2014,	53:10536-
10540.	
29.	Volker	T,	Meggers	E:	Chemical	Activation	in	Blood	Serum	and	Human	Cell	Culture:	
Improved	Ruthenium	Complex	for	Catalytic	Uncaging	of	Alloc-Protected	Amines.	
Chembiochem	2017,	18:1083-1086.	
30.	Sanchez	MI,	Penas	C,	Vazquez	ME,	Mascarenas	JL:	Metal-catalyzed	uncaging	of	DNA-
binding	agents	in	living	cells.	Chem	Sci	2014,	5:1901-1907.	
31.	Hsu	HT,	Trantow	BM,	Waymouth	RM,	Wender	PA:	Bioorthogonal	Catalysis:	A	General	
Method	To	Evaluate	Metal-Catalyzed	Reactions	in	Real	Time	in	Living	Systems	
Using	a	Cellular	Luciferase	Reporter	System.	Bioconjug	Chem	2016,	27:376-382.	
32.	Tomas-Gamasa	M,	Martinez-Calvo	M,	Couceiro	JR,	Mascarenas	JL:	Transition	metal	
catalysis	in	the	mitochondria	of	living	cells.	Nat	Commun	2016,	7:12538.	
33.	Murphy	MP:	Targeting	lipophilic	cations	to	mitochondria.	Biochim	Biophys	Acta	2008,	
1777:1028-1031.	
34.	Smith	RA,	Porteous	CM,	Gane	AM,	Murphy	MP:	Delivery	of	bioactive	molecules	to	
mitochondria	in	vivo.	Proc	Natl	Acad	Sci	U	S	A	2003,	100:5407-5412.	
35.	Logan	A,	Pell	VR,	Shaffer	KJ,	Evans	C,	Stanley	NJ,	Robb	EL,	Prime	TA,	Chouchani	ET,	
Cocheme	HM,	Fearnley	IM,	et	al.:	Assessing	the	Mitochondrial	Membrane	Potential	
in	Cells	and	In	Vivo	using	Targeted	Click	Chemistry	and	Mass	Spectrometry.	Cell	
Metab	2016,	23:379-385.	
36.	Chalmers	S,	Caldwell	ST,	Quin	C,	Prime	TA,	James	AM,	Cairns	AG,	Murphy	MP,	McCarron	
JG,	Hartley	RC:	Selective	uncoupling	of	individual	mitochondria	within	a	cell	using	a	
mitochondria-targeted	photoactivated	protonophore.	J	Am	Chem	Soc	2012,	
134:758-761.	
37.	Sadhu	KK,	Eierhoff	T,	Romer	W,	Winssinger	N:	Photoreductive	uncaging	of	fluorophore	
in	response	to	protein	oligomers	by	templated	reaction	in	vitro	and	in	cellulo.	J	Am	
Chem	Soc	2012,	134:20013-20016.	
38.	Sadhu	KK,	Lindberg	E,	Winssinger	N:	In	cellulo	protein	labelling	with	Ru-conjugate	for	
luminescence	imaging	and	bioorthogonal	photocatalysis.	Chem	Commun	(Camb)	
2015,	51:16664-16666.	
39.	Holtzer	L,	Oleinich	I,	Anzola	M,	Lindberg	E,	Sadhu	KK,	Gonzalez-Gaitan	M,	Winssinger	N:	
Nucleic	Acid	Templated	Chemical	Reaction	in	a	Live	Vertebrate.	ACS	Cent	Sci	2016,	
2:394-400.	
17	
••		
A	 Ru-complex	 was	 linked	 to	 PNA-probes	 targeting	 specific	 microRNAs.	 Rhodamine	 was	
relased	through	photoreduction	of	an	azide	by	the	Ru-complex.	The	expresssion	of	miRNAs	
in	specific	tissues	was	monitored	by	fluorescence.	This	established	a	nucleic	acid-templated	
chemical	reaction	in	live	vertebrates.	
	
40.	Jeschek	M,	Reuter	R,	Heinisch	T,	Trindler	C,	Klehr	J,	Panke	S,	Ward	TR:	Directed	
evolution	of	artificial	metalloenzymes	for	in	vivo	metathesis.	Nature	2016,	537:661-
665.	
••		
Binding	of	biotinylated	Ru-complexes	to	streptavidin	creates	artificial	metalloenzymes	(ArMs).	These	
ArMs	catalyze	an	olefin	metathesis	in	the	periplasm	of	E.	coli.	The	artificial	metathase	was	improved	
through	the	directed	evolution	of	streptavidin.	The	in	cellulo	catalysis	facilitated	an	efficient	and	fast	
screening	process.	The	evolved	ArM	outperforms	the	standard	ring	closing	metathesis	catalysts.			
	
41.	Li	N,	Lim	RK,	Edwardraja	S,	Lin	Q:	Copper-free	Sonogashira	cross-coupling	for	
functionalization	of	alkyne-encoded	proteins	in	aqueous	medium	and	in	bacterial	
cells.	J	Am	Chem	Soc	2011,	133:15316-15319.	
42.	Liu	CC,	Schultz	PG:	Adding	new	chemistries	to	the	genetic	code.	Annu	Rev	Biochem	
2010,	79:413-444.	
	
43.	Davis	L,	Chin	JW:	Designer	proteins:	applications	of	genetic	code	expansion	in	cell	
biology.	Nat	Rev	Mol	Cell	Biol	2012,	13:168-182.	
44.	Spicer	CD,	Triemer	T,	Davis	BG:	Palladium-mediated	cell-surface	labeling.	J	Am	Chem	
Soc	2012,	134:800-803.	
45.	Li	J,	Lin	S,	Wang	J,	Jia	S,	Yang	M,	Hao	Z,	Zhang	X,	Chen	PR:	Ligand-free	palladium-
mediated	site-specific	protein	labeling	inside	gram-negative	bacterial	pathogens.	J	
Am	Chem	Soc	2013,	135:7330-7338.	
46.	Li	N,	Ramil	CP,	Lim	RK,	Lin	Q:	A	genetically	encoded	alkyne	directs	palladium-mediated	
protein	labeling	on	live	mammalian	cell	surface.	ACS	Chem	Biol	2015,	10:379-384.	
47.	Li	J,	Yu	J,	Zhao	J,	Wang	J,	Zheng	S,	Lin	S,	Chen	L,	Yang	M,	Jia	S,	Zhang	X,	et	al.:	Palladium-
triggered	deprotection	chemistry	for	protein	activation	in	living	cells.	Nat	Chem	
2014,	6:352-361.	
••	
The	 authors	 used	 Pd-complexes	 for	 gain-of-function	 studies	 in	 HeLa	 cells.	 Unnatural	 amino	 acids	
were	encoded	in	OspF	by	amber	stop	codon	suppression.	The	incorporation	of	a	protected	lysine	in	
OspF	 inhibits	 its	 enzymatic	 activity.	 The	enzyme	was	 activated	 through	 cleavage	of	 the	protecting	
group.	These	gain	of	function	approaches	allow	new	functional	studies.	
	
48.	Wang	J,	Zheng	S,	Liu	Y,	Zhang	Z,	Lin	Z,	Li	J,	Zhang	G,	Wang	X,	Li	J,	Chen	PR:	Palladium-
Triggered	Chemical	Rescue	of	Intracellular	Proteins	via	Genetically	Encoded	Allene-
Caged	Tyrosine.	J	Am	Chem	Soc	2016,	138:15118-15121.	
49.	Indrigo	E,	Clavadetscher	J,	Chankeshwara	SV,	Megia-Fernandez	A,	Lilienkampf	A,	Bradley	
M:	Intracellular	delivery	of	a	catalytic	organometallic	complex.	Chem	Commun	
(Camb)	2017,	53:6712-6715.	
•	
A	 Pd-catalyst	was	 conjugated	 to	 a	 cell-penetrating	 peptide.	 This	 new	 type	 of	 catalytic	 system	has	
improved	cell	uptake	rates.	The	Pd-complex	unmasks	rhodamine	in	prostate	cancer	cells.		
18	
	
50.	Zahid	M,	Robbins	PD:	Cell-type	specific	penetrating	peptides:	therapeutic	promises	and	
challenges.	Molecules	2015,	20:13055-13070.	
51.	Svensen	N,	Walton	JG,	Bradley	M:	Peptides	for	cell-selective	drug	delivery.	Trends	
Pharmacol	Sci	2012,	33:186-192.	
52.	Sasmal	PK,	Carregal-Romero	S,	Han	AA,	Streu	CN,	Lin	Z,	Namikawa	K,	Elliott	SL,	Koster	
RW,	Parak	WJ,	Meggers	E:	Catalytic	azide	reduction	in	biological	environments.	
Chembiochem	2012,	13:1116-1120.	
53.	Bose	S,	Ngo	AH,	Do	LH:	Intracellular	Transfer	Hydrogenation	Mediated	by	Unprotected	
Organoiridium	Catalysts.	J	Am	Chem	Soc	2017,	139:8792-8795.	
54.	Tsubokura	K,	Vong	KK,	Pradipta	AR,	Ogura	A,	Urano	S,	Tahara	T,	Nozaki	S,	Onoe	H,	Nakao	
Y,	Sibgatullina	R,	et	al.:	In	Vivo	Gold	Complex	Catalysis	within	Live	Mice.	Angew	
Chem	Int	Ed	Engl	2017,	56:3579-3584.	
••	
Au-complexes	were	 exploited	 to	 specifically	 label	 intestine	 and	 liver	 of	 live	mice.	 The	Au-complex	
was	 targeted	to	 these	organs	by	 linking	 it	 to	coumarin.	This	coumarin-Au-complex	binds	with	high	
affinity	 to	 albumins.	 In	 turn,	 the	 albumins	 were	 directed	 to	 liver	 and	 intestine	 by	 an	 N-glycan	
coating.		
	
	
	
	
